Bisphosphonates inhibit angiogenesis in Vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats

Cancer Research

Volumn 62, Issue 22, 2002, Pages 6538-6544

  Fournier, Pierrick ^a   Boissier, Sandrine ^a   Filleur, Stéphanie ^b   Guglielmi, Julien ^a   Cabon, Florence ^b   Colombel, Marc ^a   Clézardin, Philippe ^a  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; LUCIFERASE; RISEDRONIC ACID; TESTOSTERONE; ZOLEDRONIC ACID;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; BONE BIOPSY; BONE METASTASIS; CASTRATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG TISSUE LEVEL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VENTRAL LOBE; RAT; REPORTER GENE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE AND BONES; CELL DIVISION; CELLS, CULTURED; CLODRONIC ACID; DIPHOSPHONATES; ENDOTHELIUM, VASCULAR; EPITHELIAL CELLS; ETIDRONIC ACID; HUMANS; IMIDAZOLES; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; ORCHIECTOMY; OSTEITIS DEFORMANS; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE; TISSUE DISTRIBUTION;

EID: 0037112368     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rogers, M. J., Gordon. S., Benford. H. L., Coxon, F. P., Luckman. S. P., Monkkonen, J., and Frith, J. C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer (Phila.), 86: 2961-2978, 2000
2. Guise, T. A., and Mundy, G. R. Cancer and bone. Endocr. Rev., 19: 18-54, 1998
3. Hillner, B. E., Ingle, J. N., Berenson. J. R., Janjan, N. A., Albain, K. S., Lipton, A., Yee, G., Biermann, J. S., Chlebowski, R. T., and Pfister. D. G. American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. American society of clinical oncology bisphosphonates expert panel. J. Clin. Oncol., 18: 1378-1391, 2000
4. van der Pluijm, G., Vloedgraven, H., van Beck, E., van der Wee-Pals, L., Löwik. C., and Papapoulos, S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Investig., 98: 698-705, 1996
5. Boissier, S., Magnetto, S., Frappart, L., Cuzin. B., Ebetino, F. H., and Clézardin, P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res., 57: 3890-3894, 1997
6. Boissier, S., Ferreras, M., Peyruchaud, O., Magnetto, S., Ebetino, F. H., Colombel, M., Delmas, P., Delaisse, J. M., and Clezardin, P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res., 60: 2949-2954, 2000
7. Senaratne, S. G., Pirianov, G., Mansi, J. L., Amett, T. R., and Colston, K. W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer. 82: 1459-1468, 2000
8. Lee, M. V., Fong, E. M., Singer, F. R., and Guenette, R. S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res., 61: 2602-2608, 2001
9. Virtanen, S. S., Väänänen, H. K., Härkönen, P. L., and Lakkakorpi, P. T. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res., 62: 2708-2714, 2002
10. Peyruchaud. O., Winding, B., Pdcheur. I., Serre. C. M., Delmas. P., and Cledzardin, P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J. Bone Miner. Res., 16: 2027-2034, 2001
11. Gerber, H. P., and Ferrara. N. Angiogenesis and bone growth. Trends Cardiovasc. Med., 10: 223-228, 2000
12. Meunier, P. J., Chapuy, M. C., Alexandre, C., Bressot, C., Edouard, C., Vignon, C., Mathieu, L., and Trechsel. U. Effects of disodium dichloromethylene diphosphonate on Paget’s disease of bone. Lancet. 2: 489-492, 1979
13. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996
14. Zhang, S., Gu, J., Yang, N. S., Kao, C., Gardner, T. A., Eble, J. N., and Cheng. L. Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. Prostate. 51: 286-292, 2002
15. Delmas, P. D., Chapuy, M. C., Vignon. E., Charhon, S., Briancon. D., Alexandre, C., Edouard. C., and Meunier. P. J. Long term effects of dichloromethylene diphosphonate in Paget’s disease of bone. J. Clin. Endocrinol. Metab., 54: 837-843, 1982
16. Franck-Lissbrant, I., Häggström, S., Damber, J. E., and Bergh, A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology, 139: 451-456, 1998
17. CIézardin, P., Frappart, L., Clerget, M., Péchoux, C., and Delmas, P. Expression of thrombospondin (TSP) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res., 53: 1421-1430, 1993
18. English, H. F., Drago, J. R., and Santen, R. J. Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiographic and morphometrical analysis. Prostate. 7: 41-51, 1997
19. Lin, J. H. Bisphosphonates: A review of their pharmacokinetic properties. Bone, 18: 75-85, 1986
20. Valle. B. L. Biochemistry, physiology and pathology of zinc. Physiol. Rev., 39: 443-490, 1992
21. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., and Rodan, G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Investig., 88: 2095-2105, 1991
22. Hiraga, T., Williams, P. J., Mundy, G. R., and Yoneda, T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res., 61: 4418-4424, 2001
23. Santini, D., Vincenzi, B., Avvisati, G., Dicuonzo, G., Battistoni. F., Gavasci, M., Salerno, A., Denaro, V., and Tonini, G. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res., 8: 1080-1084, 2002
24. 2MDP) in the chicken-chorioallantoic membrane assay-preliminary report. In: O. L. M Bijvoet and A. Lipton (eds.), Osteoclast Inhibition in the Management of Malignancy-Related Bone Disorders, pp. 86-88. Lewiston, NY: Hogrefe and Huber Publishers. 1990
25. Wood. J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy. L., Foidart, J. M., Castronovo. V., and Green, J. R. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther., 302: 1055-1061, 2002